What diseases does fostatinib/fotantinib mainly treat?

Fostamatinib is a targeted drug mainly used to treat chronic immune thrombocytopenia (ITP). Immune thrombocytopenia is a disease caused by the immune system mistakenly attacking and destroying platelets, the cellular components that help blood clot. Patients with ITP often face insufficient platelet counts, which can lead to easy bleeding, bruising, and the risk of serious bleeding. Traditional treatments often include corticosteroids, immunoglobulins, and other immunosuppressants, but these treatments may be ineffective or patients may become resistant to them.

Fostatinib, as aSyk (spleen tyrosine kinase) inhibitor, mainly regulates the immune response by inhibiting the activity of Syk enzyme, thereby reducing the immune system's attack on platelets. The Syk enzyme plays an important role in signal transduction of immune cells, especially the activation of B cells and macrophages. By blocking the signaling of the Syk enzyme, fostatinib reduces the immune response and reduces platelet destruction, thereby increasing platelet levels in the patient's blood.

Fostatinib is usually used after conventional treatments have failed. It provides an effective treatment option for ITP patients whose disease cannot be controlled by other treatments. Compared with other treatment options, fostatinib can regulate the immune system through a more specific mechanism, thereby reducing unnecessary immune responses, and has achieved significant efficacy in some patients, increasing the number of platelets and effectively reducing the occurrence of bleeding events.

Although fostatinib is an innovative drug for the treatmentITP, its application is not limited to this. With the deepening of research, the potential of fostatinib in other immune-related diseases is also constantly being explored. For example, several studies are evaluating fostatinib in the treatment of other immune system disorders, particularly those involving immune cell activation and platelet destruction.

Reference materials:https://ec.europa.eu/health/documents/community-register/2020/20200109146735/anx_146735_en.pdf